OncoMatch/Clinical Trials/NCT07014410
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Is NCT07014410 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies pyrotinib dalpiciclib letrozole for breast cancer.
Treatment: pyrotinib dalpiciclib letrozole — This is a a multicenter Phase II clinical study investigating efficacy of pyrotinib combined with dalpiciclib combined with letrozole in ER-positive and HER2-positive advanced breast cancer patients. The sample size is 63.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive expression
positive ER expression
Required: HER2 (ERBB2) positive expression
positive HER2 expression
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: cdk4/6 inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify